These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27617402)

  • 1. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.
    de Jong Y; van Maldegem AM; Marino-Enriquez A; de Jong D; Suijker J; Briaire-de Bruijn IH; Kruisselbrink AB; Cleton-Jansen AM; Szuhai K; Gelderblom H; Fletcher JA; Bovée JV
    Lab Invest; 2016 Oct; 96(10):1128-37. PubMed ID: 27617402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
    van Oosterwijk JG; Herpers B; Meijer D; Briaire-de Bruijn IH; Cleton-Jansen AM; Gelderblom H; van de Water B; Bovée JV
    Ann Oncol; 2012 Jun; 23(6):1617-26. PubMed ID: 22112972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
    de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
    Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
    van Oosterwijk JG; Meijer D; van Ruler MA; van den Akker BE; Oosting J; Krenács T; Picci P; Flanagan AM; Liegl-Atzwanger B; Leithner A; Athanasou N; Daugaard S; Hogendoorn PC; Bovée JV
    Am J Pathol; 2013 Apr; 182(4):1347-56. PubMed ID: 23415961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
    Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
    Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC
    Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
    Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
    Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
    Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
    Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens.
    Anvekar RA; Asciolla JJ; Lopez-Rivera E; Floros KV; Izadmehr S; Elkholi R; Belbin G; Sikora AG; Chipuk JE
    Cell Death Dis; 2012 Nov; 3(11):e420. PubMed ID: 23152056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.